The current stock price of BVS is 7.99 USD. In the past month the price increased by 4.13%. In the past year, price decreased by -22.48%.
ChartMill assigns a technical rating of 7 / 10 to BVS. When comparing the yearly performance of all stocks, BVS is a bad performer in the overall market: 76.08% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to BVS. While BVS is still in line with the averages on profitability rating, there are concerns on its financial health.
Over the last trailing twelve months BVS reported a non-GAAP Earnings per Share(EPS) of 0.59. The EPS increased by 51.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.39% | ||
| ROA | 1.11% | ||
| ROE | 4.71% | ||
| Debt/Equity | 1.93 |
7 analysts have analysed BVS and the average price target is 15.3 USD. This implies a price increase of 91.49% is expected in the next year compared to the current price of 7.99.
For the next year, analysts expect an EPS growth of 41.83% and a revenue growth 0.33% for BVS
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 18.16 | 16.217B | ||
| ALGN | ALIGN TECHNOLOGY INC | 17.61 | 14.082B | ||
| SOLV | SOLVENTUM CORP | 12.55 | 13.956B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 19.67 | 4.875B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.81 | 4.454B | ||
| ICUI | ICU MEDICAL INC | 18.08 | 3.783B | ||
| XRAY | DENTSPLY SIRONA INC | 8.8 | 2.78B | ||
| HAE | HAEMONETICS CORP/MASS | 10.51 | 2.763B | ||
| NEOG | NEOGEN CORP | 31.52 | 2.332B | ||
| UFPT | UFP TECHNOLOGIES INC | 26.12 | 2.063B |
View all stocks in the Health Care Supplies Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 950 full-time employees. The company went IPO on 2021-02-11. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. The company offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
BIOVENTUS INC - A
4721 Emperor Boulevard, Suite 100
Durham NORTH CAROLINA 27703 US
CEO: Kenneth M. Reali
Employees: 950
Phone: 19194746700
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 950 full-time employees. The company went IPO on 2021-02-11. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. The company offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
The current stock price of BVS is 7.99 USD. The price decreased by -0.99% in the last trading session.
BVS does not pay a dividend.
BVS has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
BVS stock is listed on the Nasdaq exchange.
The PE ratio for BIOVENTUS INC - A (BVS) is 13.54. This is based on the reported non-GAAP earnings per share of 0.59 and the current share price of 7.99 USD.
You can find the ownership structure of BIOVENTUS INC - A (BVS) on the Ownership tab.